Metabolic Diversity in Tumors Assessed by 18F-FDG PET/CT as a Prognostic Indicator in Diffuse Large B-Cell Lymphoma - Top-Institutions - MDSpire

Metabolic Diversity in Tumors Assessed by 18F-FDG PET/CT as a Prognostic Indicator in Diffuse Large B-Cell Lymphoma

  • By

  • Wenchong Xin

  • Fei Wang

  • Luo Lu

  • Haoyu Zang

  • Bai He

  • Weiying Gu

  • Yuetao Wang

  • November 24, 2025

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology-Oncology
    • Nuclear Medicine
    • Radiology

  • #2

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Hematology-Oncology
    • Nuclear Medicine
    • Molecular Imaging

  • #3

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology-Oncology
    • Nuclear Medicine
    • Cancer Imaging

  • #4

    Johns Hopkins Hospital
    Johns Hopkins Hospital

    Baltimore, MD

    Key Differentiators

    • Hematology-Oncology
    • Nuclear Medicine
    • Radiology

  • #5

    University of Pennsylvania (Perelman School of Medicine)
    University of Pennsylvania (Perelman School of Medicine)

    Philadelphia, PA

    Key Differentiators

    • Hematology-Oncology
    • Nuclear Medicine
    • Molecular Imaging

Original Source(s)

Metabolic Diversity in Tumors Assessed by 18F-FDG PET/CT as a Prognostic Indicator in Diffuse Large B-Cell Lymphoma

  • by Wenchong Xin, Fei Wang, Luo Lu, Haoyu Zang, Bai He, Weiying Gu, Yuetao Wang

  • November 24, 2025

Related Content

Emerging applications of artificial intelligence for risk stratification in head and neck cancer: a scoping review

FOXA2 in cancer: from fundamental biology to clinical translation

Myelodysplastic syndromes complicated by atypical Sweet syndrome: a brief research report